Finanzen von Microbot Medical Inc (MBOT)MBOTMicrobot Medical Inc

Evaluating the bottom line, Microbot Medical Inc maintains a gross margin of -266.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2567.63%, while the net margin is -2334.85%. These profitability ratios, combined with a Return on Equity (ROE) of -32.91%, provide a clear picture of how effectively MBOT converts its operational activities into shareholder value.

In the context of the broader market, MBOT competes directly with industry leaders such as CGTX and GUTS. With a market capitalization of $99.40M, it holds a significant position in the sector. When comparing efficiency, MBOT's gross margin of -266.80% stands against CGTX's N/A and GUTS's N/A. Such benchmarking helps identify whether Microbot Medical Inc is trading at a premium or discount relative to its financial performance.

Microbot Medical has shown significant revenue growth, with Q2 2026 revenue exceeding Q1 by over 100%. However, it has reported consistent net losses, with a net income loss of $5,627,000 in Q2 2026.